How Good are Bacteriophages as an Alternative Therapy to Mitigate Biofilms of Nosocomial Infections

References

• Rode DKH, Singh PK, Drescher K. Multicellular and unicellular responses of microbial biofilms to stress. Biol Chem. 2020;401(12). doi:10.1515/hsz-2020-0213
   Web of Science ®Google Scholar
• Flemming H-C. Biofilms. In: Encyclopedia of Life Sciences. John Wiley & Sons, Ltd; 2008. doi10.1002/9780470015902.a0000342.pub2
   Google Scholar
• Hutchings M, Truman A, Wilkinson B. Antibiotics: past, present and future. Curr Opin Microbiol. 2019;51. doi:10.1016/j.mib.2019.10.008
   Web of Science ®Google Scholar
• Banerjee A, Batabyal K, Singh AD, et al. Multi-drug resistant, biofilm-producing high-risk clonal lineage of Klebsiella in companion and household animals. Lett Appl Microbiol. 2020;71(6). doi:10.1111/lam.13381
   Web of Science ®Google Scholar
• Szafrański SP, Winkel A, Stiesch M. The use of bacteriophages to biocontrol oral biofilms. J Biotechnol. 2017;250:29–44. doi:10.1016/j.jbiotec.2017.01.002
   PubMed Web of Science ®Google Scholar
• Abebe GM. The Role of bacterial biofilm in antibiotic resistance and food contamination. Int J Microbiol. 2020;2020. doi:10.1155/2020/1705814
   Web of Science ®Google Scholar
• Human Microbiome Project Consortium T. Structure, function and diversity of the healthy human microbiome The Human Microbiome Project Consortium*; 2012. doi:10.1038/nature11234
   Google Scholar
• Kriebel K, Hieke C, Müller-Hilke B, Nakata M, Kreikemeyer B. Oral biofilms from symbiotic to pathogenic interactions and associated disease - Connection of periodontitis and rheumatic arthritis by peptidylarginine deiminase. Front Microbiol. 2018;9(JAN). doi:10.3389/fmicb.2018.00053
   Web of Science ®Google Scholar
• Caton JG, Armitage G, Berglundh T, et al. A new classification scheme for periodontal and peri-implant diseases and conditions – introduction and key changes from the 1999 classification. J Clin Periodontol. 2018;45. doi:10.1111/jcpe.12935
   Web of Science ®Google Scholar
• How KY, Song KP, Chan KG. Porphyromonas gingivalis: an overview of periodontopathic pathogen below the gum line. Front Microbiol. 2016;7(FEB):53. doi:10.3389/fmicb.2016.00053
   Web of Science ®Google Scholar
• Chatzigiannidou I, Teughels W, Van de Wiele T, Boon N. Oral biofilms exposure to chlorhexidine results in altered microbial composition and metabolic profile. Npj Biofilms Microbiomes. 2020;6(1). doi:10.1038/s41522-020-0124-3
   PubMed Web of Science ®Google Scholar
• van Belleghem JD, Manasherob R, Miȩdzybrodzki R, et al. The rationale for using bacteriophage to treat and prevent periprosthetic joint infections. Front Microbiol. 2020;11. doi:10.3389/fmicb.2020.591021
   Web of Science ®Google Scholar
• Chatterjee S, Maiti PK, Dey R, Kundu AK, Dey RK. Biofilms on indwelling urologic devices: microbes and antimicrobial management prospect. Ann Med Health Sci Res. 2014;4(1):100–104. doi:10.4103/2141-9248.126612
   Google Scholar
• Cortese YJ, Wagner VE, Tierney M, Devine D, Fogarty A. Review of catheter-associated urinary tract infections and in vitro urinary tract models. J Healthc Eng. 2018;2018:1–16. doi:10.1155/2018/2986742
   Web of Science ®Google Scholar
• Feneley RCL, Hopley IB, Wells PNT. Urinary catheters: history, current status, adverse events and research agenda. J Med Eng Technol. 2015;39(8):459–470. doi:10.3109/03091902.2015.1085600
   PubMedGoogle Scholar
• Jordan RP, Malic S, Waters MG, Stickler DJ, Williams DW. Development of an antimicrobial urinary catheter to inhibit urinary catheter encrustation. Microbiol Discov. 2015;3(1):1. doi:10.7243/2052-6180-3-1
   Google Scholar
• Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37(6):1771–1776. doi:10.1128/jcm.37.6.1771-1776.1999
   PubMed Web of Science ®Google Scholar
• Olsen I. Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis. 2015;34(5):877–886. doi:10.1007/s10096-015-2323-z
   PubMed Web of Science ®Google Scholar
• Uruén C, Chopo-Escuin G, Tommassen J, Mainar-Jaime RC, Arenas J. Biofilms as promoters of bacterial antibiotic resistance and tolerance. Antibiot. 2020;10(1):1–36. doi:10.3390/antibiotics1001000321
   Google Scholar
• Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. Biomed Res Int. 2016;2016. doi:10.1155/2016/2475067
   PubMed Web of Science ®Google Scholar
• Antimicrobial resistance. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed June 27, 2021.
   Google Scholar
• Nelson RE, Hatfield KM, Wolford H, et al. National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clin Infect Dis. 2021;72(Supplement_1):S17–S26. doi:10.1093/cid/ciaa1581
   PubMed Web of Science ®Google Scholar
• Global action plan on antimicrobial resistance. Available from: https://www.who.int/publications/i/item/9789241509763. Accessed June 27, 2021.
   Google Scholar
• Manohar P, Tamhankar AJ, Lundborg CS, Nachimuthu R. Therapeutic characterization and efficacy of bacteriophage cocktails infecting Escherichia coli, Klebsiella pneumoniae, and Enterobacter species. Front Microbiol. 2019;10(MAR):574. doi:10.3389/fmicb.2019.00574
   Web of Science ®Google Scholar
• Moghadam MT, Amirmozafari N, Shariati A, et al. How phages overcome the challenges of drug resistant bacteria in clinical infections. Infect Drug Resist. 2020;13:45–61. doi:10.2147/IDR.S234353
   PubMed Web of Science ®Google Scholar
• Gutiérrez D, Fernández L, Rodríguez A, García P. Are phage lytic proteins the secret weapon to kill Staphylococcus aureus? mBio. 2018;9(1):e01923–e02017. doi:10.1128/mBio.01923-17
   Web of Science ®Google Scholar
• Sharahi JY, Azimi T, Shariati A, Safari H, Tehrani MK, Hashemi A. Advanced strategies for combating bacterial biofilms. J Cell Physiol. 2019;234(9):14689–14708. doi:10.1002/jcp.28225
   Web of Science ®Google Scholar
• Renner LD, Weibel DB. Physicochemical regulation of biofilm formation. MRS Bull. 2011;36(5). doi:10.1557/mrs.2011.65
   Web of Science ®Google Scholar
• O’Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol. 2000;54. doi:10.1146/annurev.micro.54.1.49
   Web of Science ®Google Scholar
• Topka-Bielecka G, Dydecka A, Necel A, et al. Bacteriophage-derived depolymerases against bacterial biofilm. Antibiotics. 2021;10:175–196. doi:10.3390/antibiotics10020175
   Web of Science ®Google Scholar
• Rabin N, Zheng Y, Opoku-Temeng C, Du Y, Bonsu E, Sintim HO. Biofilm formation mechanisms and targets for developing antibiofilm agents. Future Med Chem. 2015;7(4). doi:10.4155/fmc.15.6
   Web of Science ®Google Scholar
• Behzadi P. Classical chaperone-usher (CU) adhesive fimbriome: uropathogenic Escherichia coli (UPEC) and urinary tract infections (UTIs). Folia Microbiol (Praha). 2020;65(1):45–65. doi:10.1007/s12223-019-00719-x
   PubMed Web of Science ®Google Scholar
• Behzadi P. Uropathogenic Escherichia coli and fimbrial adhesins virulome. Urin Tract Infect. 2017. doi:10.5772/INTECHOPEN.71374
   Google Scholar
• Werneburg GT, Thanassi DG. Pili assembled by the chaperone/usher pathway in Escherichia coli and salmonella. EcoSal Plus. 2018;8(1). doi:10.1128/ecosalplus.ESP-0007-2017
   PubMedGoogle Scholar
• Baby S, Kumar Karnaker V. Adhesins of uropathogenic Escherichia coli (UPEC). IP Int J Med Microbiol Trop Dis. 2021;2(1):10–18.
   Google Scholar
• Subashchandrabose S, Mobley HLT. Virulence and fitness determinants of uropathogenic Escherichia coli. Microbiol Spectr. 2015;3(4). doi:10.1128/MICROBIOLSPEC.UTI-0015-2012
   Google Scholar
• Ribić R, Meštrović T, Neuberg M, Kozina G. Effective anti-adhesives of uropathogenic Escherichia coli. Acta Pharm. 2018;68(1):1–18. doi:10.2478/ACPH-2018-0004
   Web of Science ®Google Scholar
• Wurpel DJ, Totsika M, Allsopp LP, Webb RI, Moriel DG, Schembri MA. Comparative proteomics of uropathogenic Escherichia coli during growth in human urine identify UCA-like (UCL) fimbriae as an adherence factor involved in biofilm formation and binding to uroepithelial cells. J Proteomics. 2016;131:177–189. doi:10.1016/J.JPROT.2015.11.001
   Web of Science ®Google Scholar
• Hozzari A, Behzadi P, Kerishchi Khiabani P, Sholeh M, Sabokroo N. Clinical cases, drug resistance, and virulence genes profiling in Uropathogenic Escherichia coli. J Appl Genet. 2020;61(2):265–273. doi:10.1007/s13353-020-00542-y
   PubMed Web of Science ®Google Scholar
• Jahandeh N, Ranjbar R, Behzadi P, Behzadi E. Uropathogenic Escherichia coli virulence genes: invaluable approaches for designing DNA microarray probes. Cent Eur J Urol. 2015;68(4):452–458. doi:10.5173/ceju.2015.625
   PubMed Web of Science ®Google Scholar
• Foster TJ. Surface proteins of Staphylococcus epidermidis. Front Microbiol. 2020;11. doi:10.3389/fmicb.2020.01829
   Web of Science ®Google Scholar
• Ferreira A, Gray M, Wiedmann M, Boor KJ. Comparative genomic analysis of the sigB operon in Listeria monocytogenes and in other Gram-positive bacteria. Curr Microbiol. 2004;48(1):39–46. doi:10.1007/S00284-003-4020-X
   Web of Science ®Google Scholar
• Vorkapic D, Pressler K, Schild S. Multifaceted roles of extracellular DNA in bacterial physiology. Curr Genet. 2016;62(1):71–79. doi:10.1007/S00294-015-0514-X
   PubMed Web of Science ®Google Scholar
• Arciola CR, Campoccia D, Montanaro L. Implant infections: adhesion, biofilm formation and immune evasion. Nat Rev Microbiol. 2018;16(7):397–409. doi:10.1038/S41579-018-0019-Y
   PubMed Web of Science ®Google Scholar
• Boles BR, Horswill AR. agr-mediated dispersal of staphylococcus aureus biofilms. PLOS Pathog. 2008;4(4):e1000052. doi:10.1371/JOURNAL.PPAT.1000052
   PubMed Web of Science ®Google Scholar
• Xue T, Ni J, Shang F, Chen X, Zhang M. Autoinducer-2 increases biofilm formation via an ica- and bhp-dependent manner in Staphylococcus epidermidis RP62A. Microbes Infect. 2015;17(5):345–352. doi:10.1016/J.MICINF.2015.01.003
   PubMed Web of Science ®Google Scholar
• Patel JD, Colton E, Ebert M, Anderson JM. Gene expression during S. epidermidis biofilm formation on biomaterials. J Biomed Mater Res Part A. 2012;100A(11):2863–2869. doi:10.1002/JBM.A.34221
   Web of Science ®Google Scholar
• Lister JL, Horswill AR. Staphylococcus aureus biofilms: recent developments in biofilm dispersal. Front Cell Infect Microbiol. 2014;4(DEC). doi:10.3389/FCIMB.2014.00178
   Web of Science ®Google Scholar
• Wang R, Khan BA, Cheung GYC, et al. Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice. J Clin Invest. 2011;121(1):238. doi:10.1172/JCI42520
   PubMed Web of Science ®Google Scholar
• Kostakioti M, Hadjifrangiskou M, Hultgren SJ. Bacterial biofilms: development, dispersal, and therapeutic strategies in the Dawn of the postantibiotic era. Cold Spring Harb Perspect Med. 2013;3(4). doi:10.1101/cshperspect.a010306
   Web of Science ®Google Scholar
• Sarshar M, Behzadi P, Scribano D, Palamara AT, Ambrosi C. Acinetobacter baumannii: an ancient commensal with weapons of a pathogen. Pathogens. 2021;10(4). doi:10.3390/pathogens10040387
   Web of Science ®Google Scholar
• Geisinger E, Huo W, Hernandez-Bird J, Isberg RR. Acinetobacter baumannii: envelope determinants that control drug resistance, virulence, and surface variability. Annu Rev Microbiol. 2019;73:481–506. doi:10.1146/annurev-micro-020518-115714
   PubMed Web of Science ®Google Scholar
• Tomaras AP, Flagler MJ, Dorsey CW, Gaddy JA, Actis LA. Characterization of a two-component regulatory system from Acinetobacter baumannii that controls biofilm formation and cellular morphology. Microbiology. 2008;154(11):3398–3409. doi:10.1099/MIC.0.2008/019471-0
   Web of Science ®Google Scholar
• Eze EC, Chenia HY, El Zowalaty ME. Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect Drug Resist. 2018;11:2277–2299. doi:10.2147/IDR.S169894
   PubMed Web of Science ®Google Scholar
• Colquhoun JM, Rather PN. Insights into mechanisms of biofilm formation in Acinetobacter baumannii and implications for uropathogenesis. Front Cell Infect Microbiol. 2020;10. doi:10.3389/fcimb.2020.00253
   Web of Science ®Google Scholar
• Harding CM, Pulido MR, Di Venanzio G, et al. Pathogenic Acinetobacter species have a functional type I secretion system and contact-dependent inhibition systems. J Biol Chem. 2017;292(22):9075–9087. doi:10.1074/JBC.M117.781575
   PubMed Web of Science ®Google Scholar
• Scavone P, Iribarnegaray V, Caetano AL, Schlapp G, Härtel S, Zunino P. Fimbriae have distinguishable roles in Proteus mirabilis biofilm formation. Pathog Dis. 2016;74(5):1–9. doi:10.1093/femspd/ftw033
   Web of Science ®Google Scholar
• Behzadi P, Baráth Z, Gajdács M. It’s not easy being green: a narrative review on the microbiology, virulence and therapeutic prospects of multidrug-resistant Pseudomonas aeruginosa. Antibiotics. 2021;10(1):1–29. doi:10.3390/antibiotics10010042
   Web of Science ®Google Scholar
• Thuenauer R, Landi A, Trefzer A, et al. The pseudomonas aeruginosa lectin LecB causes integrin internalization and inhibits epithelial wound healing. MBio. 2020;11(2). doi:10.1128/MBIO.03260-19
   Web of Science ®Google Scholar
• Vanderwoude J, Fleming D, Azimi S, Trivedi U, Rumbaugh KP, Diggle SP. The evolution of virulence in Pseudomonas aeruginosa during chronic wound infection. Proc Biol Sci. 2020;287(1937):20202272. doi:10.1098/RSPB.2020.2272
   Web of Science ®Google Scholar
• Trunk K, Benkert B, Quäck N, et al. Anaerobic adaptation in Pseudomonas aeruginosa: definition of the Anr and Dnr regulons. Environ Microbiol. 2010;12(6):1719–1733. doi:10.1111/J.1462-2920.2010.02252.X
   Web of Science ®Google Scholar
• Li M, Long Y, Liu Y, et al. HigB of Pseudomonas aeruginosa enhances killing of phagocytes by up-regulating the Type III secretion system in Ciprofloxacin induced persister cells. Front Cell Infect Microbiol. 2016;6(OCT). doi:10.3389/FCIMB.2016.00125
   Web of Science ®Google Scholar
• Alonso VP, Queiroz MM, Gualberto ML, Nascimento MS. Klebsiella pneumonia carbapenemase (KPC), methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus spp. (VRE) in the food production chain and biofilm formation on abiotic surfaces. Curr Opin Food Sci. 2019;26:79–86. doi:10.1016/j.cofs.2019.04.002
   Web of Science ®Google Scholar
• Behzadi P, García-Perdomo HA, Karpiński TM, Issakhanian L. Metallo-ß-lactamases: a review. Mol Biol Rep. 2020;47(8):6281–6294. doi:10.1007/s11033-020-05651-9
   PubMed Web of Science ®Google Scholar
• Zheng JX, Lin ZW, Chen C, et al. Biofilm formation in Klebsiella pneumoniae bacteremia strains was found to be associated with CC23 and the presence of wcaG. Front Cell Infect Microbiol. 2018;8(FEB):21–32. doi:10.3389/fcimb.2018.00021
   Web of Science ®Google Scholar
• Rowe MC, Withers HL, Swift S. Uropathogenic Escherichia coli forms biofilm aggregates under iron restriction that disperse upon the supply of iron. FEMS Microbiol Lett. 2010;307(1). doi:10.1111/j.1574-6968.2010.01968.x
   Web of Science ®Google Scholar
• Wood TL, Gong T, Zhu L, et al. Rhamnolipids from Pseudomonas aeruginosa disperse the biofilms of sulfate-reducing bacteria. Npj Biofilms Microbiomes. 2018;4:22. doi:10.1038/s41522-018-0066-1
   Web of Science ®Google Scholar
• Guilhen C, Forestier C, Balestrino D. Biofilm dispersal: multiple elaborate strategies for dissemination of bacteria with unique properties. Mol Microbiol. 2017;105(2). doi:10.1111/mmi.13698
   Web of Science ®Google Scholar
• Roizman D, Vidaillac C, Givskov M, Yang L. In vitro evaluation of biofilm dispersal as a therapeutic strategy to restore antimicrobial efficacy. Antimicrob Agents Chemother. 2017;61(10). doi:10.1128/AAC.01088-17
   Web of Science ®Google Scholar
• Olivares E, Badel-Berchoux S, Provot C, Prévost G, Bernardi T, Jehl F. Clinical impact of antibiotics for the treatment of Pseudomonas aeruginosa biofilm infections. Front Microbiol. 2020;10:2894. doi:10.3389/fmicb.2019.02894
   Web of Science ®Google Scholar
• Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010;8(9):623–633. doi:10.1038/nrmicro2415
   PubMed Web of Science ®Google Scholar
• Flemming HC, Wingender J, Szewzyk U, Steinberg P, Rice SA. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016;14(9). doi:10.1038/nrmicro.2016.94
   Web of Science ®Google Scholar
• Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41(3). doi:10.1093/femsre/fux010
   Web of Science ®Google Scholar
• Hathroubi S, Mekni MA, Domenico P, Nguyen D. Biofilms: microbial shelters against antibiotics. Microb Drug Resist. 2017;23(2):147–156. doi:10.1089/mdr.2016.0087
   PubMed Web of Science ®Google Scholar
• Pena RT, Blasco L, Ambroa A, et al. Relationship between quorum sensing and secretion systems. Front Microbiol. 2019;10:1100. doi:10.3389/fmicb.2019.01100
   PubMed Web of Science ®Google Scholar
• Stalder T, Top E. Plasmid transfer in biofilms: a perspective on limitations and opportunities. Npj Biofilms Microbiomes. 2016;2:16022. doi:10.1038/npjbiofilms.2016.22
   PubMed Web of Science ®Google Scholar
• Brito IL. Examining horizontal gene transfer in microbial communities. Nat Rev Microbiol. 2021;19(7):442–453. doi:10.1038/s41579-021-00534-7
   PubMed Web of Science ®Google Scholar
• Mehta HH, Prater AG, Beabout K, et al. The essential role of hypermutation in rapid adaptation to antibiotic stress. Antimicrob Agents Chemother. 2019;63(7). doi:10.1128/AAC.00744-19
   Web of Science ®Google Scholar
• van Acker H, Coenye T. The role of efflux and physiological adaptation in biofilm tolerance and resistance. J Biol Chem. 2016;291(24):12565–12572. doi:10.1074/jbc.R115.707257
   Web of Science ®Google Scholar
• Brackman G, Breyne K, De Rycke R, et al. The quorum sensing inhibitor hamamelitannin increases antibiotic susceptibility of staphylococcus aureus biofilms by affecting peptidoglycan biosynthesis and eDNA release. Sci Rep. 2016;6:20321. doi:10.1038/srep20321
   PubMed Web of Science ®Google Scholar
• Tashiro Y, Eida H, Ishii S, Futamata H, Okabe S. Generation of small colony variants in biofilms by Escherichia coli harboring a conjugative F plasmid. Microbes Environ. 2017;32(1):40–46. doi:10.1264/jsme2.ME16121
   Web of Science ®Google Scholar
• Mirani ZA, Aziz M, Khan SI. Small colony variants have a major role in stability and persistence of Staphylococcus aureus biofilms. J Antibiot (Tokyo). 2015;68(2):98–105. doi:10.1038/ja.2014.115
   Web of Science ®Google Scholar
• Fauvart M, de Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol. 2011;60(6). doi:10.1099/jmm.0.030932-0
   Web of Science ®Google Scholar
• Ng WL, Bassler BL. Bacterial quorum-sensing network architectures. Annu Rev Genet. 2009;43:197–222. doi:10.1146/annurev-genet-102108-134304
   PubMed Web of Science ®Google Scholar
• Rasool FN, Saavedra MA, Pamba S, et al. Isolation and characterization of human pathogenic multidrug resistant bacteria associated with plastic litter collected in Zanzibar. J Hazard Mater. 2021;405. doi:10.1016/j.jhazmat.2020.124591
   Web of Science ®Google Scholar
• Govaert M, Smet C, Walsh JL, Van Impe JFM. Dual-species model biofilm consisting of Listeria monocytogenes and Salmonella typhimurium: development and inactivation with cold atmospheric plasma (CAP). Front Microbiol. 2019;10. doi:10.3389/fmicb.2019.02524
   Web of Science ®Google Scholar
• Rao Y, Shang W, Yang Y, Zhou R, Rao X. Fighting mixed-species microbial biofilms with cold atmospheric plasma. Front Microbiol. 2020;11. doi:10.3389/fmicb.2020.01000
   Web of Science ®Google Scholar
• Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2). doi:10.1038/nrmicro821
   Web of Science ®Google Scholar
• Abedon ST. Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets? FEMS Microbiol Lett. 2016;363:246. doi:10.1093/femsle/fnv246
   Web of Science ®Google Scholar
• Abedon ST. Phage “delay” towards enhancing bacterial escape from biofilms: a more comprehensive way of viewing resistance to bacteriophages. AIMS Microbiol. 2017;3(2):186–226. doi:10.3934/microbiol.2017.2.186
   Web of Science ®Google Scholar
• Vestby LK, Grønseth T, Simm R, Nesse LL. Bacterial biofilm and its role in the pathogenesis of disease. Antibiotics. 2020;9(2). doi:10.3390/antibiotics9020059
   Web of Science ®Google Scholar
• Bonomo RA. β lactamases: a focus on current challenges. Cold Spring Harb Perspect Med. 2017;7:1–15.
   Web of Science ®Google Scholar
• Naas T, Oueslati S, Bonnin RA, et al. Beta-lactamase database (BLDB)–structure and function. J Enzyme Inhib Med Chem. 2017;32(1):917–919. doi:10.1080/14756366.2017.1344235
   PubMed Web of Science ®Google Scholar
• Kaplan JB. Antibiotic-induced biofilm formation. Int J Artif Organs. 2011;34(9):737–751. doi:10.5301/IJAO.5000027
   PubMed Web of Science ®Google Scholar
• Ahmadi M, Ranjbar R, Behzadi P, Mohammadian T. Virulence factors, antibiotic resistance patterns, and molecular types of clinical isolates of Klebsiella Pneumoniae. Expert Rev Anti Infect Ther. 2021. doi:10.1080/14787210.2022.1990040
   Web of Science ®Google Scholar
• Mushegian AR. Are there 1031virus particles on earth, or more, or fewer? J Bacteriol. 2020;202(9). doi:10.1128/JB.00052-20
   Web of Science ®Google Scholar
• Ackermann HW. 5500 Phages examined in the electron microscope. Arch Virol. 2007;152(2):227–243. doi:10.1007/s00705-006-0849-1
   PubMed Web of Science ®Google Scholar
• Devoto AE, Santini JM, Olm MR, et al. Megaphages infect Prevotella and variants are widespread in gut microbiomes. Nat Microbiol. 2019;4(4). doi:10.1038/s41564-018-0338-9
   Web of Science ®Google Scholar
• Hassan AY, Lin JT, Ricker N, Anany H. The age of phage: friend or foe in the new Dawn of therapeutic and biocontrol applications? Pharmaceuticals. 2021;14(3):1–36. doi:10.3390/ph14030199
   Web of Science ®Google Scholar
• Clokie MR, Millard AD, Letarov AV, Heaphy S. Phages in nature. Bacteriophage. 2011;1(1):31. doi:10.4161/BACT.1.1.14942
   PubMedGoogle Scholar
• Hansen MF, Svenningsen LS, Røder HL, Middelboe M, Burmølle M. Big impact of the tiny: bacteriophage–bacteria interactions in biofilms. Trends Microbiol. 2019;27(9):739–752. doi:10.1016/j.tim.2019.04.006
   PubMed Web of Science ®Google Scholar
• Simmons EL, Bond MC, Koskella B, Drescher K, Bucci V, Nadell CD. Biofilm structure promotes coexistence of phage-resistant and phage-susceptible bacteria. mSystems. 2020;5(3):e00877–e00919. doi:10.1128/mSystems.00877-19
   Web of Science ®Google Scholar
• Eriksen RS, Svenningsen SL, Sneppen K, Mitarai N. A growing microcolony can survive and support persistent propagation of virulent phages. Proc Natl Acad Sci U S A. 2017;115(2). doi:10.1073/pnas.1708954115
   Web of Science ®Google Scholar
• Bull JJ, Christensen KA, Scott C, Jack BR, Crandall CJ, Krone SM. Phage-bacterial dynamics with spatial structure: self organization around phage sinks can promote increased cell densities. Antibiotics. 2018;7(1):8. doi:10.3390/antibiotics7010008
   Web of Science ®Google Scholar
• Tian F, Li J, Nazir A, Tong Y. Bacteriophage – a promising alternative measure for bacterial biofilm control. Infect Drug Resist. 2021;14:205–217. doi:10.2147/IDR.S290093
   Web of Science ®Google Scholar
• Perov S, Lidor O, Salinas N, et al. Structural insights into curli CsgA cross-β fibril architecture inspire repurposing of anti-amyloid compounds as anti-biofilm agents. PLoS Pathog. 2019;15(8):e1007978. doi:10.1371/journal.ppat.1007978
   Web of Science ®Google Scholar
• Pearl S, Gabay C, Kishony R, Oppenheim A, Balaban NQ. Nongenetic individuality in the host-phage interaction. PLoS Biol. 2008;6(5):e120. doi:10.1371/journal.pbio.0060120
   PubMed Web of Science ®Google Scholar
• Taylor BP, Penington CJ, Weitz JS. Emergence of increased frequency and severity of multiple infections by viruses due to spatial clustering of hosts. Phys Biol. 2016;13(6). doi:10.1088/1478-3975/13/6/066014
   Web of Science ®Google Scholar
• Castillo-Ruiz M, Vinés ED, Montt C, et al. Isolation of a novel Aggregatibacter actinomycetemcomitans serotype b bacteriophage capable of lysing bacteria within a biofilm. Appl Environ Microbiol. 2011;77(9):3157–3159. doi:10.1128/AEM.02115-10
   PubMed Web of Science ®Google Scholar
• Høyland-Kroghsbo NM, Paczkowski J, Mukherjee S, et al. Quorum sensing controls the Pseudomonas aeruginosa CRISPR-Cas adaptive immune system. Proc Natl Acad Sci U S A. 2017;114(1):131–135. doi:10.1073/pnas.1617415113
   PubMed Web of Science ®Google Scholar
• Moreau P, Diggle SP, Friman V-P. Bacterial cell-to-cell signaling promotes the evolution of resistance to parasitic bacteriophages. Ecol Evol. 2017;7(6):1936–1941. doi:10.1002/ece3.2818
   Web of Science ®Google Scholar
• Qin X, Sun Q, Yang B, Pan X, He Y, Yang H. Quorum sensing influences phage infection efficiency via affecting cell population and physiological state. J Basic Microbiol. 2017;57(2):162–170. doi:10.1002/jobm.201600510
   Web of Science ®Google Scholar
• Erez Z, Steinberger-Levy I, Shamir M, et al. Communication between viruses guides lysis–lysogeny decisions. Nature. 2017;541(7638):488–493. doi:10.1038/nature21049
   PubMed Web of Science ®Google Scholar
• Shah M, Taylor VL, Bona D, et al. A phage-encoded anti-activator inhibits quorum sensing in Pseudomonas aeruginosa. Mol Cell. 2021;81(3):571–583.e6. doi:10.1016/j.molcel.2020.12.011
   PubMed Web of Science ®Google Scholar
• González S, Fernández L, Gutiérrez D, Campelo AB, Rodríguez A, García P. Analysis of different parameters affecting diffusion, propagation and survival of Staphylophages in bacterial biofilms. Front Microbiol. 2018;9. doi:10.3389/fmicb.2018.02348
   Web of Science ®Google Scholar
• Fischetti VA. Development of phage lysins as novel therapeutics: a historical perspective. Viruses. 2018;10(6):310. doi:10.3390/v10060310
   PubMed Web of Science ®Google Scholar
• Roach DR, Donovan DM. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage. 2015;5(3):e1062590. doi:10.1080/21597081.2015.1062590
   PubMedGoogle Scholar
• Murray E, Draper LA, Ross RP, Hill C. The advantages and challenges of using endolysins in a clinical setting. Viruses. 2021;13(4):680. doi:10.3390/v13040680
   PubMed Web of Science ®Google Scholar
• Rodríguez-Rubio L, Gerstmans H, Thorpe S, Mesnage S, Lavigne R, Briers Y. DUF3380 domain from a Salmonella phage endolysin shows potent N-acetylmuramidase activity. Appl Environ Microbiol. 2016;82(16):4975–4981. doi:10.1128/AEM.00446-16
   Web of Science ®Google Scholar
• Matamp N, Bhat SG. Phage endolysins as potential antimicrobials against multidrug resistant Vibrio alginolyticus and Vibrio parahaemolyticus: current status of research and challenges ahead. Microorganisms. 2019;7(3):84. doi:10.3390/microorganisms7030084
   Web of Science ®Google Scholar
• Abdelrahman F, Easwaran M, Daramola OI, et al. Phage-encoded endolysins. Antibiotics. 2021;10(2):1–31. doi:10.3390/antibiotics10020124
   Web of Science ®Google Scholar
• Wang I-N, Smith DL, Young R. Holins: the protein clocks of bacteriophage infections. Annu Rev Microbiol. 2000;54(1):799–825. doi:10.1146/annurev.micro.54.1.799
   Web of Science ®Google Scholar
• Łusiak-szelachowska M, Weber-Dąbrowska B, Górski A. Bacteriophages and lysins in biofilm control. Virol Sin. 2020;35(2):125–133. doi:10.1007/s12250-019-00192-3
   PubMed Web of Science ®Google Scholar
• de Miguel T, Rama JLR, Sieiro C, Sánchez S, Villa TG. Bacteriophages and lysins as possible alternatives to treat antibiotic‐resistant urinary tract infections. Antibiotics. 2020;9(8):1–11. doi:10.3390/antibiotics9080466
   Web of Science ®Google Scholar
• Ghose C, Euler CW. Gram-negative bacterial lysins. Antibiotics. 2020;9(2):74. doi:10.3390/antibiotics9020074
   Web of Science ®Google Scholar
• Huang G, Shen X, Gong Y, et al. Antibacterial properties of phage Abp1 endolysin (PlyAB1). BMC Infect Dis. 2014;14(1). doi:10.1186/s12879-014-0681-2
   Web of Science ®Google Scholar
• Lood R, Winer BY, Pelzek AJ, et al. Novel phage Lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother. 2015;59(4):1983–1991. doi:10.1128/AAC.04641-14
   PubMed Web of Science ®Google Scholar
• Wang Q, Euler CW, Delaune A, Fischetti VA. Using a novel lysin to help control Clostridium difficile infections. Antimicrob Agents Chemother. 2015;59(12):7447–7457. doi:10.1128/AAC.01357-15
   PubMed Web of Science ®Google Scholar
• Guo Z, Huang J, Yan G, et al. Identification and characterization of Dpo42, a novel depolymerase derived from the Escherichia coli phage vB_EcoM_ECOO78. Front Microbiol. 2017;8. doi:10.3389/fmicb.2017.01460
   Web of Science ®Google Scholar
• Peng S-Y, You R-I, Lai M-J, Lin N-T, Chen L-K, Chang K-C. Highly potent antimicrobial modified peptides derived from the Acinetobacter baumannii phage endolysin LysAB2. Sci Rep. 2017;7(1). doi:10.1038/s41598-017-11832-7
   Web of Science ®Google Scholar
• Wu Y, Wang R, Xu M, et al. A Novel polysaccharide depolymerase encoded by the phage SH-KP152226 confers specific activity against multidrug-resistant Klebsiella pneumoniae via biofilm degradation. Front Microbiol. 2019;10. doi:10.3389/fmicb.2019.02768
   Web of Science ®Google Scholar
• Lv M, Wang S, Yan G, et al. Genome sequencing and analysis of an Escherichia coli phage vB_EcoM-ep3 with a novel lysin, Lysep3. Virus Genes. 2015;50(3):487–497. doi:10.1007/s11262-015-1195-8
   Web of Science ®Google Scholar
• Maciejewska B, Roszniowski B, Espaillat A, et al. Klebsiella phages representing a novel clade of viruses with an unknown DNA modification and biotechnologically interesting enzymes. Appl Microbiol Biotechnol. 2017;101(2):673–684. doi:10.1007/s00253-016-7928-3
   Web of Science ®Google Scholar
• Schirmeier E, Zimmermann P, Hofmann V, et al. Inhibitory and bactericidal effect of Artilysin ® Art-175 against colistin-resistant mcr-1 -positive Escherichia coli isolates. Int J Antimicrob Agents. 2018;51(3):528–529. doi:10.1016/j.ijantimicag.2017.08.027
   PubMed Web of Science ®Google Scholar
• Gerstmans H, Rodríguez-Rubio L, Lavigne R, Briers Y. From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria. Biochem Soc Trans. 2016;44(1):123–128. doi:10.1042/BST20150192
   PubMed Web of Science ®Google Scholar
• Raz A, Serrano A, Hernandez A, Euler CW, Fischetti VA. Isolation of phage lysins that effectively kill Pseudomonas aeruginosa in mouse models of lung and skin infection. Antimicrob Agents Chemother. 2019;63(7). doi:10.1128/AAC.00024-19
   Web of Science ®Google Scholar
• Paradis-Bleau C, Cloutier I, Lemieux L, et al. Peptidoglycan lytic activity of the Pseudomonas aeruginosa phage φKZ gp144 lytic transglycosylase. FEMS Microbiol Lett. 2007;266(2):201–209. doi:10.1111/j.1574-6968.2006.00523.x
   Web of Science ®Google Scholar
• Cheng Q, Nelson D, Zhu S, Fischetti VA. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother. 2005;49(1):111–117. doi:10.1128/AAC.49.1.111-117.2005
   PubMed Web of Science ®Google Scholar
• Oliveira H, Pinto G, Oliveira A, et al. Characterization and genome sequencing of a Citrobacter freundii phage CfP1 harboring a lysin active against multidrug-resistant isolates. Appl Microbiol Biotechnol. 2016;100(24):10543–10553. doi:10.1007/s00253-016-7858-0
   Web of Science ®Google Scholar
• Loeffler JM, Fischetti VA. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob Agents Chemother. 2003;47(1):375–377. doi:10.1128/AAC.47.1.375-377.2003
   PubMed Web of Science ®Google Scholar
• Domenech M, Garciá E, Moscoso M. In vitro destruction of Streptococcus pneumoniae biofilms with bacterial and phage peptidoglycan hydrolases. Antimicrob Agents Chemother. 2011;55(9):4144–4148. doi:10.1128/AAC.00492-11
   PubMed Web of Science ®Google Scholar
• Corsini B, Díez-Martínez R, Aguinagalde L, et al. Chemotherapy with phage lysins reduces pneumococcal colonization of the respiratory tract. Antimicrob Agents Chemother. 2018;62(6). doi:10.1128/AAC.02212-17
   Web of Science ®Google Scholar
• Gilmer DB, Schmitz JE, Euler CW, Fischetti VA. Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2013;57(6):2743–2750. doi:10.1128/AAC.02526-12
   PubMed Web of Science ®Google Scholar
• Jun SY, Jung GM, Yoon SJ, et al. Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother. 2014;58(4):2084–2088. doi:10.1128/AAC.02232-13
   PubMed Web of Science ®Google Scholar
• Xia F, Li X, Wang B, et al. Combination therapy of LysGH15 and Apigenin as a new strategy for treating pneumonia caused by Staphylococcus aureus. Appl Environ Microbiol. 2016;82(1):87–94. doi:10.1128/AEM.02581-15
   PubMed Web of Science ®Google Scholar
• Gil F, Grzegorzewicz AE, Catalão MJ, Vital J, McNeil MR, Pimentel M. Mycobacteriophage Ms6 LysB specifically targets the outer membrane of Mycobacterium smegmatis. Microbiology. 2010;156(5):1497–1504. doi:10.1099/mic.0.032821-0
   Web of Science ®Google Scholar
• Grover N, Paskaleva EE, Mehta KK, Dordick JS, Kane RS. Growth inhibition of Mycobacterium smegmatis by mycobacteriophage-derived enzymes. Enzyme Microb Technol. 2014;63:1–6. doi:10.1016/j.enzmictec.2014.04.018
   PubMed Web of Science ®Google Scholar
• Latka A, Maciejewska B, Majkowska-Skrobek G, Briers Y, Drulis-Kawa Z. Bacteriophage-encoded virion-associated enzymes to overcome the carbohydrate barriers during the infection process. Appl Microbiol Biotechnol. 2017;101(8):3103–3119. doi:10.1007/s00253-017-8224-6
   PubMed Web of Science ®Google Scholar
• Fernandes S, São-José C. Enzymes and mechanisms employed by tailed bacteriophages to breach the bacterial cell barriers. Viruses. 2018;10(8):396. doi:10.3390/v10080396
   Web of Science ®Google Scholar
• Pires DP, Melo LDR, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy as an alternative or complementary strategy to prevent and control biofilm-related infections. Curr Opin Microbiol. 2017;39:48–56. doi:10.1016/j.mib.2017.09.004
   PubMed Web of Science ®Google Scholar
• Yan J, Mao J, Xie J. Bacteriophage polysaccharide depolymerases and biomedical applications. BioDrugs. 2014;28(3):265–274. doi:10.1007/s40259-013-0081-y
   PubMed Web of Science ®Google Scholar
• Hsieh S-E, Lo -H-H, Chen S-T, Lee M-C, Tseng Y-H. Wide host range and strong lytic activity of Staphylococcus aureus Lytic Phage Stau2. Appl Environ Microbiol. 2011;77(3):756–761. doi:10.1128/AEM.01848-10
   PubMed Web of Science ®Google Scholar
• Oliveira A, Ribeiro HG, Silva AC, et al. Synergistic antimicrobial interaction between honey and phage against Escherichia coli biofilms. Front Microbiol. 2017;8. doi:10.3389/fmicb.2017.02407
   Web of Science ®Google Scholar
• Vikram A, Woolston J, Sulakvelidze A. Phage biocontrol applications in food production and processing. Curr Issues Mol Biol. 2020;40:267–302. doi:10.21775/cimb.040.267
   PubMed Web of Science ®Google Scholar
• Ding C, He J. Effect of antibiotics in the environment on microbial populations. Appl Microbiol Biotechnol. 2010;87(3):925–941. doi:10.1007/s00253-010-2649-5
   PubMed Web of Science ®Google Scholar
• Luong T, Salabarria A-C, Edwards RA, Roach DR. Standardized bacteriophage purification for personalized phage therapy. Nat Protoc. 2020;15(9):2867–2890. doi:10.1038/s41596-020-0346-0
   PubMed Web of Science ®Google Scholar
• Melo LDR, Oliveira H, Pires DP, Dabrowska K, Azeredo J. Phage therapy efficacy: a review of the last 10 years of preclinical studies. Crit Rev Microbiol. 2020;46(1):78–99. doi:10.1080/1040841X.2020.1729695
   PubMed Web of Science ®Google Scholar
• Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111–114. doi:10.4161/bact.1.2.14590
   PubMedGoogle Scholar
• Tinoco JM, Buttaro B, Zhang H, Liss N, Sassone L, Stevens R. Effect of a genetically engineered bacteriophage on Enterococcus faecalis biofilms. Arch Oral Biol. 2016;71:80–86. doi:10.1016/j.archoralbio.2016.07.001
   PubMed Web of Science ®Google Scholar
• Schmerer M, Molineux IJ, Bull JJ. Synergy as a rationale for phage therapy using phage cocktails. PeerJ. 2014;2014(1). doi:10.7717/peerj.590
   Web of Science ®Google Scholar
• Ferriol-González C, Domingo-Calap P. Phages for biofilm removal. Antibiotics. 2020;9(5):268. doi:10.3390/antibiotics9050268
   Web of Science ®Google Scholar
• Carrascosa C, Raheem D, Ramos F, Saraiva A, Raposo A. Microbial biofilms in the food industry—a comprehensive review. Int J Environ Res Public Health. 2021;18(4):1–31. doi:10.3390/ijerph18042014
   Web of Science ®Google Scholar
• Tacconelli E, Carrara E, Savoldi A, Kattula D, Burkert F. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; 2017. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/. Accessed May 12, 2021.
   Google Scholar
• Khalifa L, Gelman D, Shlezinger M, et al. Defeating antibiotic- and phage-resistant Enterococcus faecalis using a phage cocktail in vitro and in a clot model. Front Microbiol. 2018;9. doi:10.3389/fmicb.2018.00326
   Web of Science ®Google Scholar
• Dalmasso M, De Haas E, Neve H, et al. Isolation of a novel phage with activity against Streptococcus mutans biofilms. PLoS One. 2015;10(9):e0138651. doi:10.1371/journal.pone.0138651
   PubMed Web of Science ®Google Scholar
• Dakheel KH, Rahim RA, Neela VK, et al. Genomic analyses of two novel biofilm-degrading methicillin-resistant Staphylococcus aureus phages. BMC Microbiol. 2019;19(1):1–23. doi:10.1186/s12866-019-1484-9
   PubMed Web of Science ®Google Scholar
• Bagińska N, Cieślik M, Górski A, Jończyk-Matysiak E. The role of antibiotic resistant A. baumannii in the pathogenesis of urinary tract infection and the potential of its treatment with the use of bacteriophage therapy. Antibiotics. 2021;10(3):281. doi:10.3390/antibiotics10030281
   Web of Science ®Google Scholar
• Montso PK, Mlambo V, Ateba CN. Efficacy of novel phages for control of multi-drug resistant Escherichia coli O177 on artificially contaminated beef and their potential to disrupt biofilm formation. Food Microbiol. 2021;94:103647. doi:10.1016/j.fm.2020.103647
   PubMed Web of Science ®Google Scholar
• Roach DR, Leung CY, Henry M, et al. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe. 2017;22(1):38–47.e4. doi:10.1016/j.chom.2017.06.018
   PubMed Web of Science ®Google Scholar
• Tabassum R, Shafique M, Amer Khawaja K, et al. Complete genome analysis of a Siphoviridae phage TSK1 showing biofilm removal potential against Klebsiella pneumoniae OPEN. Sci Rep. 2018;8(1):17904–undefined. doi:10.1038/s41598-018-36229-y
   Web of Science ®Google Scholar
• Li M, Shi D, Li Y, et al. Recombination of T4-like Phages and its activity against pathogenic Escherichia coli in planktonic and biofilm forms. Virol Sin. 2020;35(5):651–661. doi:10.1007/s12250-020-00233-2
   Web of Science ®Google Scholar
• Arumugam SN, Rudraradhya AC, Sadagopan S, Sukumaran S, Sambasivam G, Ramesh N. Analysis of susceptibility patterns of Pseudomonas aeruginosa and Isolation, Characterization of lytic bacteriophages targeting multi drug resistant pseudomonas aeruginosa. Biomed Pharmacol J. 2018;11(2):1105–1117. doi:10.13005/bpj/1471
   Google Scholar
• Sinha A, Eniyan K, Manohar P, Ramesh N, Bajpai U. Characterization and genome analysis of B1 sub-cluster mycobacteriophage PDRPxv. Virus Res. 2020;279:197884. doi:10.1016/j.virusres.2020.197884
   Web of Science ®Google Scholar
• Waters EM, Neill DR, Kaman B, et al. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax. 2017;72(7):666–667. doi:10.1136/thoraxjnl-2016-209265
   PubMed Web of Science ®Google Scholar
• Alves DR, Perez-Esteban P, Kot W, et al. A novel bacteriophage cocktail reduces and disperses Pseudomonas aeruginosa biofilms under static and flow conditions. Microb Biotechnol. 2016;9(1):61–74. doi:10.1111/1751-7915.12316
   PubMed Web of Science ®Google Scholar
• Forti F, Roach DR, Cafora M, et al. Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob Agents Chemother. 2018;62(6). doi:10.1128/AAC.02573-17
   Web of Science ®Google Scholar
• Kaur S, Harjai K, Chhibber S, Becker K. In vivo assessment of phage and Linezolid based implant coatings for treatment of Methicillin resistant S. aureus (MRSA) mediated orthopaedic device related infections. PLoS One. 2016;11(6):e0157626. doi:10.1371/journal.pone.0157626
   PubMed Web of Science ®Google Scholar
• Ooi ML, Drilling AJ, Morales S, et al. Safety and tolerability of bacteriophage therapy for chronic rhinosinusitis due to Staphylococcus aureus. JAMA Otolaryngol - Head Neck Surg. 2019;145(8):723–729. doi:10.1001/jamaoto.2019.1191
   PubMed Web of Science ®Google Scholar
• Yilmaz C, Colak M, Yilmaz BC, Ersoz G, Kutateladze M, Gozlugol M. Bacteriophage therapy in implant-related infections: an experimental study. J Bone Jt Surg - Ser A. 2013;95(2):117–125. doi:10.2106/JBJS.K.01135
   PubMed Web of Science ®Google Scholar
• Kishor C, Mishra R, Saraf S, Kumar M, Srivastav A, Nath G. Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Indian J Med Res. 2016;143(1). doi:10.4103/0971-5916.178615
   Web of Science ®Google Scholar
• Gibb BP, Hadjiargyrou M. Bacteriophage therapy for bone and joint infections. Bone Joint J. 2021;103-B(2):234–244. doi:10.1302/0301-620X.103B2.BJJ-2020-0452.R2
   Web of Science ®Google Scholar
• Maszewska A, Zygmunt M, Grzejdziak I, Różalski A. Use of polyvalent bacteriophages to combat biofilm of Proteus mirabilis causing catheter-associated urinary tract infections. J Appl Microbiol. 2018;125(5):1253–1265. doi:10.1111/jam.14026
   PubMed Web of Science ®Google Scholar
• Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob Agents Chemother. 2010;54(1):397–404. doi:10.1128/AAC.00669-09
   PubMed Web of Science ®Google Scholar
• Wasfi R, Hamed SM, Amer MA, Fahmy LI. Proteus mirabilis biofilm: development and therapeutic strategies. Front Cell Infect Microbiol. 2020;10. doi:10.3389/fcimb.2020.00414
   Web of Science ®Google Scholar
• Melo LDR, Veiga P, Cerca N, et al. Development of a phage cocktail to control Proteus mirabilis catheter-associated urinary tract infections. Front Microbiol. 2016;7:1024. doi:10.3389/fmicb.2016.01024
   PubMed Web of Science ®Google Scholar
• Gomaa S, Serry F, Abdellatif H, Abbas H. Elimination of multidrug-resistant Proteus mirabilis biofilms using bacteriophages. Arch Virol. 2019;164(9):2265–2275. doi:10.1007/s00705-019-04305-x
   Web of Science ®Google Scholar
• Lehman SM, Donlan RM. Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model. Antimicrob Agents Chemother. 2015;59(2). doi:10.1128/AAC.03786-14
   Web of Science ®Google Scholar
• Malik S, Sidhu PK, Rana JS, Nehra K. Managing urinary tract infections through phage therapy: a novel approach. Folia Microbiol (Praha). 2020;65(2):217–231. doi:10.1007/s12223-019-00750-y
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Yasuda M, Uchiyama J, et al. T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections. Arch Virol. 2008;153(3). doi:10.1007/s00705-007-0031-4
   Web of Science ®Google Scholar
• Chibeu A, Lingohr EJ, Masson L, et al. Bacteriophages with the ability to degrade uropathogenic Escherichia coli biofilms. Viruses. 2012;4(4). doi:10.3390/v4040471
   Web of Science ®Google Scholar
• Chadha P, Katare OP, Chhibber S. In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. Microb Pathog. 2016;99:68–77. doi:10.1016/j.micpath.2016.08.001
   PubMed Web of Science ®Google Scholar
• Motlagh AM, Bhattacharjee AS, Goel R. Biofilm control with natural and genetically-modified phages. World J Microbiol Biotechnol. 2016;32(4). doi:10.1007/s11274-016-2009-4
   Web of Science ®Google Scholar
• Manohar P, Loh B, Athira S, et al. Phage antibiotic therapy. Front Microbiol. 2020;11:1134–1149. doi:10.3389/fmicb.2020.01434
   Web of Science ®Google Scholar
• Morrisette T, Kebriaei R, Lev KL, Morales S, Rybak MJ. Bacteriophage therapeutics: a primer for clinicians on phage-antibiotic combinations. Pharmacotherapy. 2020;40(2):153–168. doi:10.1002/phar.2358
   Web of Science ®Google Scholar
• Comeau AM, Té F, Trojet SN. Phage-antibiotic synergy (PAS): β-Lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One. 2007;2(8):e799–undefined. doi:10.1371/journal.pone.0000799
   PubMed Web of Science ®Google Scholar
• Tkhilaishvili T, Lombardi L, Klatt AB, Trampuz A, Di Luca M. Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus. Int J Antimicrob Agents. 2018;52(6). doi:10.1016/j.ijantimicag.2018.09.006
   Web of Science ®Google Scholar
• Coulter LB, Rohde RE, Aron GM. Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses. 2014;6(10):3778–3786. doi:10.3390/v6103778
   Web of Science ®Google Scholar
• Oechslin F, Piccardi P, Mancini S, et al. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J Infect Dis. 2017;215(5):703–712. doi:10.1093/infdis/jiw632
   PubMed Web of Science ®Google Scholar
• Chaudhry WN, Concepció N-Acevedo J, Park T, Andleeb S, Bull JJ, Levin BR. Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS One. 2017;12(1):e0168615. doi:10.1371/journal.pone.0168615
   PubMed Web of Science ®Google Scholar
• Sass P, Bierbaum G. Lytic activity of recombinant bacteriophage φ11 and φ12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol. 2007;73(1):347–352. doi:10.1128/AEM.01616-06
   Web of Science ®Google Scholar
• Gondil VS, Harjai K, Chhibber S. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections. Int J Antimicrob Agents. 2020;55(2). doi:10.1016/j.ijantimicag.2019.11.001
   Web of Science ®Google Scholar
• Schuch R, Khan BK, Raz A, Rotolo JA, Wittekind M. Bacteriophage lysin CF-301, a potent antistaphylococcal biofilm agent. Antimicrob Agents Chemother. 2017;61(7). doi:10.1128/AAC.02666-16
   PubMed Web of Science ®Google Scholar
• Vander EN, Linden SB, Lavigne R, Meyer E, Briers Y, Nelson DC. Characterization of the bacteriophage-derived endolysins plyss2 and plyss9 with in vitro lytic activity against bovine mastitis Streptococcus uberis. Antibiotics. 2020;9(9). doi:10.3390/antibiotics9090621
   Web of Science ®Google Scholar
• Wang S, Gu J, Lv M, et al. The antibacterial activity of E. coli bacteriophage lysin lysep3 is enhanced by fusing the Bacillus amyloliquefaciens bacteriophage endolysin binding domain D8 to the C-terminal region. J Microbiol. 2017;55(5):403–408. doi:10.1007/s12275-017-6431-6
   Web of Science ®Google Scholar
• Gutiérrez D, Ruas-Madiedo P, Martínez B, Rodríguez A, García P. Effective removal of staphylococcal biofilms by the endolysin LysH5. PLoS One. 2014;9(9):e107307. doi:10.1371/journal.pone.0107307
   PubMed Web of Science ®Google Scholar
• Hernandez-Morales AC, Lessor LL, Wood TL, et al. Genomic and biochemical characterization of Acinetobacter podophage petty reveals a novel lysis mechanism and tail-associated depolymerase activity. J Virol. 2018;92(6). doi:10.1128/jvi.01064-17
   Web of Science ®Google Scholar
• Mi L, Liu Y, Wang C, et al. Identification of a lytic Pseudomonas aeruginosa phage depolymerase and its anti-biofilm effect and bactericidal contribution to serum. Virus Genes. 2019. doi:10.1007/s11262-019-01660-4
   Web of Science ®Google Scholar
• Olsen NMC, Thiran E, Hasler T, et al. Synergistic removal of static and dynamic Staphylococcus aureus biofilms by combined treatment with a bacteriophage endolysin and a polysaccharide depolymerase. Viruses. 2018;10(8). doi:10.3390/v10080438
   Web of Science ®Google Scholar
• Geredew Kifelew L, Mitchell JG, Speck P. Mini-review: efficacy of lytic bacteriophages on multispecies biofilms. Biofouling. 2019;35(4). doi:10.1080/08927014.2019.1613525
   Web of Science ®Google Scholar
• Chan B, Abedon S. Bacteriophages and their enzymes in biofilm control. Curr Pharm Des. 2014;21(1). doi:10.2174/1381612820666140905112311
   Web of Science ®Google Scholar
• Lampp JW, Griswold KE. Alginate lyase exhibits catalysis-independent biofilm dispersion and antibiotic synergy. Antimicrob Agents Chemother. 2013;57(1). doi:10.1128/AAC.01789-12
   Web of Science ®Google Scholar
• Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc Natl Acad Sci U S A. 2007;104(27):11197–11202. doi:10.1073/pnas.0704624104
   PubMed Web of Science ®Google Scholar
• Møller-Olsen C, Ho SFS, Shukla RD, Feher T, Sagona AP. Engineered K1F bacteriophages kill intracellular Escherichia coli K1 in human epithelial cells. Sci Rep. 2018;8(1). doi:10.1038/s41598-018-35859-6
   Web of Science ®Google Scholar
• Lemon DJ, Kay MK, Titus JK, et al. Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018. J Microbiol. 2019;57(6). doi:10.1007/s12275-019-8686-6
   Web of Science ®Google Scholar
• Yosef I, Manor M, Kiro R, Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria. Proc Natl Acad Sci U S A. 2015;112(23). doi:10.1073/pnas.1500107112
   Web of Science ®Google Scholar
• Vázquez R, García E, García P. Phage lysins for fighting bacterial respiratory infections: a new generation of antimicrobials. Front Immunol. 2018;9. doi:10.3389/fimmu.2018.02252
   Web of Science ®Google Scholar
• Poonacha N, Nair S, Desai S, et al. Efficient killing of planktonic and biofilm-embedded coagulase-negative staphylococci by bactericidal protein P128. Antimicrob Agents Chemother. 2017;61(8). doi:10.1128/AAC.00457-17
   Web of Science ®Google Scholar
• Sharma U, Vipra A, Channabasappa S. Phage-derived lysins as potential agents for eradicating biofilms and persisters. Drug Discov Today. 2018;23(4). doi:10.1016/j.drudis.2018.01.026
   Web of Science ®Google Scholar
• Channabasappa S, Chikkamadaiah R, Durgaiah M, et al. Efficacy of chimeric ectolysin P128 in drug-resistant Staphylococcus aureus bacteraemia in mice. J Antimicrob Chemother. 2018;73(12). doi:10.1093/jac/dky365
   Web of Science ®Google Scholar
• Nair S, Desai S, Poonacha N, Vipra A, Sharma U. Antibiofilm activity and synergistic inhibition of Staphylococcus aureus biofilms by bactericidal protein P128 in combination with antibiotics. Antimicrob Agents Chemother. 2016;60(12). doi:10.1128/AAC.01118-16
   Web of Science ®Google Scholar
• Singh PK, Donovan DM, Kumar A. Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from Staphylococcus aureus endophthalmitis. Antimicrob Agents Chemother. 2014;58(8). doi:10.1128/AAC.00126-14
   Web of Science ®Google Scholar
• Huang L, Luo D, Gondil VS, et al. Construction and characterization of a chimeric lysin ClyV with improved bactericidal activity against Streptococcus agalactiae in vitro and in vivo. Appl Microbiol Biotechnol. 2020;104(4):1609–1619. doi:10.1007/s00253-019-10325-z
   PubMed Web of Science ®Google Scholar
• Fowler VG, Das AF, Lipka-Diamond J, et al. Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis. J Clin Invest. 2020;130(7). doi:10.1172/JCI136577
   Web of Science ®Google Scholar
• Watson A, Sauve K, Cassino C, Schuch R. Exebacase demonstrates in vitro synergy with a broad range of antibiotics against both methicillin-resistant and methicillin-susceptible staphylococcus aureus. Antimicrob Agents Chemother. 2020;64(2). doi:10.1128/AAC.01885-19
   Web of Science ®Google Scholar
• Briers Y, Walmagh M, Grymonprez B, et al. Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014;58(7). doi:10.1128/AAC.02668-14
   Web of Science ®Google Scholar
• Heselpoth RD, Euler CW, Schuch R, Fischetti VA. Lysocins: bioengineered antimicrobials that deliver lysins across the outer membrane of Gram-negative bacteria. Antimicrob Agents Chemother. 2019;63(6). doi:10.1128/AAC.00342-19
   PubMed Web of Science ®Google Scholar
• Harcombe WR, Bull JJ. Impact of phages on two-species bacterial communities. Appl Environ Microbiol. 2005;71(9). doi:10.1128/AEM.71.9.5254-5259.2005
   Web of Science ®Google Scholar
• Akanda ZZ, Taha M, Abdelbary H. Current review—The rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections. J Orthop Res. 2018;36(4):1051–1060. doi:10.1002/jor.23755
   PubMed Web of Science ®Google Scholar
• Brovko LY, Anany H, Griffiths MW. Bacteriophages for Detection and control of bacterial pathogens in food and food-processing environment. In: Advances in Food and Nutrition Research. Vol. 67. Academic Press Inc.; 2012:241–288. doi:10.1016/B978-0-12-394598-3.00006-X
   Google Scholar
• Malik DJ. Bacteriophage encapsulation using spray drying for phage therapy. Curr Issues Mol Biol. 2021;40:303–316. doi:10.21775/cimb.040.303
   Web of Science ®Google Scholar
• Pinto AM, Cerqueira MA, Bañobre-Lópes M, Pastrana LM, Sillankorva S. Bacteriophages for chronic wound treatment: from traditional to novel delivery systems. Viruses. 2020;12(2):235. doi:10.3390/v12020235
   PubMed Web of Science ®Google Scholar
• Morozova VV, Vlassov VV, Tikunova NV. Applications of bacteriophages in the treatment of localized infections in humans. Front Microbiol. 2018;9:1696. doi:10.3389/fmicb.2018.01696
   Web of Science ®Google Scholar
• Górski A, Borysowski J, Międzybrodzki R. Phage therapy: towards a successful clinical trial. Antibiotics. 2020;9(11):1–7. doi:10.3390/antibiotics9110827
   Web of Science ®Google Scholar
• Yan W, Banerjee P, Liu Y, et al. Development of thermosensitive hydrogel wound dressing containing Acinetobacter baumannii phage against wound infections. Int J Pharm. 2021;602:120508. doi:10.1016/j.ijpharm.2021.120508
   Web of Science ®Google Scholar
• Markoishvili K, Tsitlanadze G, Katsarava R, Morris JG, Sulakvelidze A. A novel sustained-release matrix based on biodegradable poly (ester amide) s and impregnated with bacteriophages and an antibiotic shows promise in management of infected venous stasis ulcers and other poorly healing wounds. Int J Dermatol. 2002;41:453–458. doi:10.1046/j.1365-4362.2002.01451.x
   PubMed Web of Science ®Google Scholar
• Sarhan WA, Azzazy HM. Apitherapeutics and phage-loaded nanofibers as wound dressings with enhanced wound healing and antibacterial activity. Nanomedicine. 2017;12(17). doi:10.2217/nnm-2017-0151
   Web of Science ®Google Scholar
• Tkhilaishvili T, Wang L, Tavanti A, Trampuz A, Di Luca M. Antibacterial efficacy of two commercially available bacteriophage formulations, Staphylococcal bacteriophage and PYO bacteriophage, against Methicillin-resistant Staphylococcus aureus: prevention and eradication of biofilm formation and control of a systemic infection of Galleria mellonella larvae. Front Microbiol. 2020;11. doi:10.3389/fmicb.2020.00110
   Web of Science ®Google Scholar
• Principi N, Silvestri E, Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol. 2019;10:1–9. doi:10.3389/fphar.2019.00513
   PubMed Web of Science ®Google Scholar
• Dennehy JJ, Abedon ST. Bacteriophage Ecology. In: Bacteriophages. Springer International Publishing; 2020:1–42. doi:10.1007/978-3-319-40598-8_8-1
   Google Scholar